Tyrosine kinase inhibitorPhase 3 trialInvestigational
Sotorasib
How it works
Blocks the activity of a protein called KRAS, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— KRAS-mutated
Pancreatic Cancer— KRAS G12C-mutated
Efficacy
In clinical trials, patients with KRAS-mutated lung cancer treated with Sotorasib had a median progression-free survival of approximately 6.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Sotorasib Outperforms Docetaxel in Lung Cancer Treatment | Lung Cancer | observational | Sotorasib was associated with a 36.7% decreased risk of death and a 43.3% decreased risk of treatment discontinuation or death compared to docetaxel. | Source → |
| Testing Sotorasib for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining two treatments shows promise for lung cancer | Lung Cancer | preclinical | The sotorasib-T-DXd combination induced deeper and more durable tumor regressions than either monotherapy, including in SR xenograft models. | Source → |
| KRAS Inhibitor Resistance Linked to AURKA Signaling | Lung Cancer | lab-study | — | Source → |
| KRAS G12C Lung Cancer Study in Japan Finds Limited Second-Line Treatment Uptake | Lung Cancer | observational | — | Source → |
| Testing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Evaluating New Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing a New Treatment to Docetaxel for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Carfilzomib and Sotorasib for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Treatment for Lung Cancer: Sotorasib Shows Promise | Lung Cancer | review | SR has demonstrated significant objective response rates and progression-free survival benefits in pretreated patients with NSCLC. | Source → |
| Researchers Report Resistance to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| KRAS Inhibitor Resistance Linked to EGFR Activation | Lung Cancer | lab-study | Dual blockade of KRASG12C and EGFR showed a substantial antitumor effect in a xenograft model of sotorasib-resistant NSCLC. | Source → |
| Sotorasib Shows Promise in Advanced Lung Cancer Patients | Lung Cancer | observational | The median real-world progression-free survival was 6.3 months, and the median overall survival was 9.5 months. | Source → |
| New approaches to treating lung cancer with KRAS mutations | Lung Cancer | review | — | Source → |
| Combining Sotorasib with Other Treatments May Help Lung Cancer Patients | Lung Cancer | phase-2 | The patient achieved a significant and durable clinical benefit lasting 23 months. | Source → |
| Resistance to Cancer Treatment Sotorasib in Lung Cancer Patients | Lung Cancer | observational | One patient with acquired MET amplification achieved a renewed partial response to the combination of sotorasib and tepotinib after progression on sotorasib monotherapy. | Source → |
| New Cancer Treatment Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | The overall response rates were 30.2% for sotorasib 960 mg-panitumumab, 7.5% for sotorasib 240 mg-panitumumab, and 1.9% for investigator's choice. | Source → |
| New Combination Therapy Shows Promise in Treating Colorectal Cancer | Colorectal Cancer | phase-2 | Preliminary results demonstrate significant improvements in progression-free survival (PFS) and objective response rates. | Source → |
| Researchers Examine KRAS Inhibitors Sotorasib and Adagrasib | Lung Cancer | lab-study | — | Source → |
| Cost-Effectiveness of Sotorasib for Lung Cancer Patients in China | Lung Cancer | phase-3 | — | Source → |
| New Cancer Drug Shows Promise in Treating Rare Genetic Mutations | Colorectal Cancer | lab-study | A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response. | Source → |
| Sotorasib May Cause Liver Damage in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combining cancer drugs may improve treatment for KRAS-driven cancers | Lung Cancer | lab-study | — | Source → |
| Long-term effects of sotorasib in lung cancer patients | Lung Cancer | phase-1/2 | Sotorasib produced an ORR of 41%, median duration of response of 12.3 months, progression-free survival (PFS) of 6.3 months, overall survival (OS) of 12.5 months, and 2-year OS rate of 33%. | Source → |
| Sotorasib treatment for lung cancer: early results in French patients | Lung Cancer | observational | Sotorasib was effective in 47% of cases. | Source → |
| Sotorasib Shows Promise in Treating Lung Cancer with Untreated Brain Metastases | Lung Cancer | phase-2 | — | Source → |
| New Cancer Treatment Targets KRAS G12C Mutation in Lung Cancer | Lung Cancer | phase-2 | The overall response rate was 37.1% for sotorasib and 45% for adagrasib. | Source → |
| Rare Liver Damage Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.